Google and Biogen Idec are teaming up to crack multiple sclerosis, the latest crossover between pharma and the wearables world.
EMD Millipore has been contracted to supply raw materials to the Samsung Biologics plant where ingredients for BM-S’ anticancer monoclonal antibody Yervoy (ipilimumab) are made.
As the number of drug approvals declined between 2012 and 2013 by more than 30%, the value of new therapeutic agent approvals seems to indicate a stronger year than initially thought.
Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross Muken.
Much of the $91bn (€66bn) raised in biotech capital over the last twelve months will end up in the hands of the CRO industry, according to a survey from analyst firm Jeffries.
Reports suggest that Samsung Biologics has halted a trial of a biosimilar version of Roche and Biogen Idec's Rituxan (rituximab).
in-PharmaTechnologist.com presents its weekly round-up of pharmaceutical career climbers, including news from Eli Lilly, Hovione and Galectin.
Biogen Idec expects the market for injectable MS drugs to shrink as patients choose more convenient delivery forms.
News from Sirona, Hospira, and Biogen Idec – People on the move
in-PharmaTechnologist presents its weekly round-up of the latest changes on the pharmaceutical career ladder, including news from Sirona, Hospira, and Biogen Idec.
Amgen has partnered with non-branded drugmaker Watson to develop biosimilar cancer drugs in a deal that goes some way towards protecting its own portfolio from generic competition.
Samsung and Quintiles' biosimilars JV teams with Biogen Idec
Samsung will set up a $300m biosimilars development JV with Massachusetts, US-based Biogen Idec, building on the partnership it forged with CRO Quintiles earlier this year.
News from Genzyme, Catalent and Futura – People on the move
Outsourcing-Pharma presents its weekly round-up of the latest happenings in the world of pharmaceutical employment, including news from Genzyme, Catalent and Futura.
News from Spectrum, ProtAffin AG, Biogen Idec, and Prosonix – People on the move
Outsourcing-Pharma presents its round-up of the latest movements within the pharmaceutical industry, including news from Spectrum, ProtAffin AG, Biogen Idec, and Prosonix.
A new CEO at Patheon and appointments at Aesica – People on the move
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including a new CEO at Patheon and appointments at Aesica.
Biogen Idec terminates lixivaptan accord narrowing therapeutic focus
Biogen Idec has started shedding development programmes to stay in line with the restructuring plan and job cuts it announced earlier this month.
NexACT enables rectal delivery of biologics, say Apricus Bio
Apricus Biosciences, formerly NexMed, announce preclinical data shows NexACT technology enables rectal delivery of biologics, including human antibodies.
Elan mulls hiving-off drug delivery business again
Irish drugmaker Elan has once again raised the possibility of selling its delivery business, Elan Drug Technologies (EDT).
A reshuffle at PhRMA and manoeuvring of directors at OSI Pharmaceuticals and Biogen Idec – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including a reshuffle at PhRMA and manoeuvring of directors at OSI Pharmaceuticals and Biogen Idec.
Genzyme strengthening its quality team and appointments at ISPE and Biogen Idec – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Genzyme strengthening its quality team and appointments at ISPE and Biogen Idec.
The retirement of Biogen Idec’s CEO and appointments at Dishman and Noven – People on the move
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including the retirement of Biogen Idec’s CEO and appointments at Dishman and Noven.
FDA approves high titre manufacture of Tysabri
The FDA has approved Biogen Idec to manufacture Tysabri using a high titre process but the product’s sales have been “negatively impacted” by the cases of patients developing PML.
Elan cuts staff and offices as Tysabri wavers
Irish drugmaker Elan, which recently dropped plans to sell its Elan Drug Technologies operation, has announced job cuts and the closure of offices in a bid to save cash.
Enzon may sell Indy plant alongside specialty pharma
Pharmaceutical company Enzon may hive off its entire specialty drugs division, including a manufacturing facility in Indianapolis, US, in the face of pressure from shareholder Carl Icahn.
Billionaire 'raider' circles as Biogen put up for sale
Biogen Idec has announced it is seeking a buyer for the company and
has already received several expressions of interest - including a
reputed $23bn (€16.2bn) bid from billionaire corporate raider Carl
Biogen bags two discovery partnerships
Biogen Idec has bagged two new partnerships in the past week which
will see it involved in the search for new drugs for central
nervous system (CNS) and inflammatory ailments.
Biogen dips toe in Indian waters
US-based biotech firm Biogen Idec has decided to enter the booming
Indian market and establish its presence in the country.
Billionaire to get bigger Biogen stake?
Investment mogul Carl Icahn could get ready to buy further shares
of biotech company Biogen Idec after getting the green light from
the competition regulators.
Biogen Idec aiming for biologic Alzheimer's drug
A team of scientists at Biogen Idec have unveiled preclinical data
for a potential protein therapeutic to treat Alzheimer's, a disease
normally only attacked using small molecules due to delivery
Serono relies on Rebif to boost 3Q
Serono has announced a mixed third quarter 2005 with product sales
and total revenues weaker than predicted. Its net income beat
market consensus but the company was hit by an $18.3 million (€15.2
million) one-off charge related to...
Biogen Idec cuts staff and sells assets
US biotechnology company Biogen Idec has succumbed to the effects
of having to withdraw its multiple sclerosis drug Tysabri
(natalizumab) earlier this year, cutting 17 per cent of its
workforce and putting manufacturing facilities...
Lonza expands UK biologics facility
Lonza has started a SF 14 million (€9m) expansion of its biologics
manufacturing facility in Slough, UK, in response to what it said
was increasing demand for mammalian cell production for clinical
trials, reports Phil Taylor.
Genentech buys Biogen Idec plant for $408m
US biotechnology company Biogen Idec has said that it plans to sell
a California manufacturing plant built to produce its withdrawn
multiple sclerosis drug Tysabri (natalizumab) to Genentech,
reports Phil Taylor.
Elan break-up under discussion?
Ireland's largest home grown pharmaceutical company, Elan Holdings,
could be split up into two separate units, one focussing on
biotechnology and the other on manufacturing and drug delivery,
according to UK news reports.
New drug extends multiple sclerosis options
The first in a completely new class of drug for multiple sclerosis
has been approved in the US, opening up a new avenue of treatment
for sufferers of the debilitating diseases and potential
blockbuster revenues for developers Elan...
Biotech merger wave gathers up KS Bio
KS Biomedix has confirmed that it is in negotiations that may lead
to a merger and add to the mini-wave of consolidation sweeping over
the UK industry.
IDEC and Biogen forge biggest bio pairing in 2003
The resurgence of merger and acquisition activity in the biotech
industry shows little sign of letting up, with US companies IDEC
Pharmaceuticals and Biogen the latest to step up to the altar